Researchers conducted a multicenter, randomized trial to test the safety and effectiveness of mezagitamab. The study included 28 adults receiving mezagitamab and 13 adults receiving a placebo. Participants took the medication once weekly for eight weeks, with follow-up continuing through week 16.
The main result focused on platelet response, defined as reaching specific platelet count thresholds. Among those taking the 600 mg dose of mezagitamab, 91% achieved a platelet response. In the combined placebo groups, only 23% achieved this same response.
Regarding safety, adverse events occurred in 68% of participants taking mezagitamab and 69% of those taking placebo. Serious adverse events were reported in 14% of the mezagitamab group and 8% of the placebo group. The overall safety profile appeared similar to that of the placebo. Because this was a small Phase 2 trial, these findings are preliminary and may not reflect outcomes in larger populations.
Readers should understand that while mezagitamab showed promise in increasing platelet counts, this early evidence is not yet enough to change standard medical practice. More research is needed to confirm these results before the drug can be widely recommended for treating immune thrombocytopenia.